The central role of dysregulated kinase activity in the etiology of progressive disorders,
including cancer, has fostered incremental efforts on drug discovery programs over the past …

Currently, chemotherapy remains the standard treatment for first-and second-line
management of small cell lung cancer (SCLC). Immunotherapy has made progress in the …

Anlotinib is a new, orally administered tyrosine kinase inhibitor that targets vascular
endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR), platelet …

Background This study aimed to evaluate the efficacy and safety of anlotinib as a third-line
and subsequent treatment for patients with small cell lung cancer (SCLC). Methods We …

Simple Summary Solitary fibrous tumor (SFT) is a malignant condition that exhibits different
clinical behaviors ranging from low to high aggressive SFT, with dedifferentiated SFT (DD …

Abstract Jiangsu Chia-Tai Tianqing Pharmaceutical and Advenchen Laboratories are co-
developing anlotinib (Focus V®) for the treatment of advanced cancer. Anlotinib is an oral …

Purpose: Medullary thyroid cancer (MTC) accounts for about 2% of all thyroid cancer, but
has a relatively poor prognosis compared with differentiated thyroid cancer. Anlotinib is a …

Angiogenesis has an essential role in tumor growth and metastasis, and blocking this
pathway has been a successfully utilized strategy in the clinical treatment of cancer …

Recent advances in the field of novel anticancer agents prolong patients' survival and show
a promising future. Tyrosine kinase inhibitors and immunotherapy for lung cancer are the …

Background The efficacy and safety of multikinase inhibitor anlotinib have been confirmed in
the treatment of advanced non-small cell lung cancer (NSCLC). However, the direct …